957193-64-5

Usage

Uses

Used in Pharmaceutical Industry:
7-iodo-1H,2H,3H,4H-pyrido[2,3-b]pyrazin-2-one is used as a potential drug candidate for various therapeutic applications due to its unique chemical structure and properties. Its heterocyclic nature and the presence of an iodine atom may contribute to its biological activity and selectivity towards specific targets, making it a valuable compound for the development of new medications.
Used in Medicinal Chemistry Research:
7-iodo-1H,2H,3H,4H-pyrido[2,3-b]pyrazin-2-one serves as a research tool in medicinal chemistry, where it can be used to study the structure-activity relationships of pyrido[2,3-b]pyrazinone derivatives. This knowledge can help in the design and synthesis of novel compounds with improved pharmacological properties and therapeutic potential.
Used in Drug Development:
7-iodo-1H,2H,3H,4H-pyrido[2,3-b]pyrazin-2-one can be employed in drug development processes to create new therapeutic agents with specific mechanisms of action. Its unique chemical features may allow for the modulation of biological targets, leading to the discovery of innovative treatments for various diseases and conditions.

InChI:InChI=1/C7H6IN3O/c8-4-1-5-7(9-2-4)10-3-6(12)11-5/h1-2H,3H2,(H,9,10)(H,11,12)

Upstream product

• 426463-05-0 2-chloro-5-iodo-3-nitro-pyridine 
• 1179359-56-8 methyl N-(5-iodo-3-nitropyridin-2-yl)glycinate 
• 957193-63-4 (5-iodo-3-nitro-pyridin-2-yl-amino)-acetic acid ethyl ester 

Downstream Products

• 1238647-71-6 1-(5-chloro-2-trifluoromethyl-benzyl)-7-iodo-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one 
• 957193-71-4 1-benzyl-7-iodo-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one 

Relevant academic research and scientific papers

Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders

Phosphodiesterase (PDE) 2A inhibitors have emerged as a novel mechanism with potential therapeutic option to ameliorate cognitive dysfunction in schizophrenia or Alzheimer's disease through upregulation of cyclic nucleotides in the brain and thereby achieve potentiation of cyclic nucleotide signaling pathways. This article details the expedited optimization of our recently disclosed pyrazolo[1,5-a]pyrimidine lead compound 4b, leading to the discovery of clinical candidate 36 (TAK-915), which demonstrates an appropriate combination of potency, PDE selectivity, and favorable pharmacokinetic (PK) properties, including brain penetration. Successful identification of 36 was realized through application of structure-based drug design (SBDD) to further improve potency and PDE selectivity, coupled with prospective design focused on physicochemical properties to deliver brain penetration. Oral administration of 36 demonstrated significant elevation of 3′,5′-cyclic guanosine monophosphate (cGMP) levels in mouse brains and improved cognitive performance in a novel object recognition task in rats. Consequently, compound 36 was advanced into human clinical trials.

NITROGENATED HETEROCYCLIC COMPOUND

The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase

Dysregulation of the anaplastic lymphoma kinase (ALK) is implicated in a variety of cancers. A series of tetrahydropyrido[2,3-b]pyrazines was constructed as ring-constrained analogs of a known aminopyridine kinase scaffold. Chemistry was developed to rapidly elaborate the SAR, structural elements impacting ALK inhibitory activity were exploited, and kinase selective analogs were identified that inhibit ALK with IC50 values ～10 nM (enzyme) and ～150 nM (cell).

PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND C-MET INHIBITORS

The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may b